智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司已向联交所申请批准2542.12万股H股(相当于根据转换及上市将予转换的内资股总数目)上市及准许买卖。于2025年4月10日，联交所已授出上市批准。
基于截至本公告日期的公司股本总数，转换H股占公司股本总数约11.19%，因此，公司H股占公司股本总数的比例将因转换及上市完成而由57.83%增加至69.02%，内资股将由40.13%减少至28.94%，而非上市外资股将维持于2.04%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.